Covid Long & terrain mastocytaire PMCHS

The shared mechanism

Core insight

Mast cells at the heart of Long Covid

SARS-CoV-2 does not always disappear completely after acute infection. Viral protein fragments — notably the nucleocapsid protein — persist in the intestinal mucosa and other tissues, continuing to activate local mast cells weeks, months, or even years after the acute phase. This chronic low-grade activation generates repeated degranulation that maintains multisystemic inflammation — reproducing exactly the clinical picture of Long Covid.

The crucial question is not why the virus persists, but why some people react differently to it. The answer lies in the terrain.

Mechanistic cascade · Plain language

From infection to chronicity

🦠 SARS-CoV-2 infection The virus enters and massively activates mast cells — acute degranulation, cytokine storm.

🧬 Tissue viral persistence Protein fragments (nucleocapsid, spike) remain lodged in the intestinal wall, lymph nodes, adipocytes — invisible to standard blood tests.

⚡ Chronic mast cell activation These fragments continue stimulating local mast cells via ACE2 receptors and TLR pathways — repeated low-grade degranulation, release of histamine, tryptase, leukotrienes.

🌐 Multisystemic inflammation Low-grade inflammation simultaneously affects multiple systems: neurological (brain fog), cardiovascular (POTS, tachycardia), digestive (IBS), musculoskeletal (fatigue, pain).

❓ Why only some people? Same virus, same viral load — yet some recover fully, others don't. The determining variable: the pre-existing mast cell terrain.

A bidirectional relationship

🎯 PMCHS terrain predisposes to Long Covid

Mast cell activation threshold already lowered — the slightest signal triggers degranulation
Dysregulated HPA axis — amplified stress response, insufficient cortisol to contain inflammation
Fragile intestinal barrier — increased permeability facilitating viral fragment persistence
Already imbalanced microbiome — reduced clearance capacity
Estrogen–mast cell loop — hormonal amplification, female predominance of Long Covid

🔍 Long Covid reveals an unrecognised PMCHS

Many patients had no diagnosis before Covid — the virus was the first visible trigger
Long Covid shares 80% of its symptoms with untreated MCAS/PMCHS
Family history often reveals relatives with similar chronic symptoms pre-Covid
Mast cell stabilisers improve both conditions — significant therapeutic convergence
Long Covid may be the diagnostic entry point toward PMCHS recognition

Scientific evidence

Key study · 2026

Nucleocapsid persistence in the gut — Augustin et al., Mucosal Immunology 2026

In intestinal biopsies from Long Covid patients, SARS-CoV-2 nucleocapsid protein persists in the terminal ileum mucosa — undetectable in blood, but present in tissue. Positive zones show intestinal barrier dysfunction (elevated zonulin) and increased local immune activity with myeloid cell enrichment and a pro-inflammatory transcriptional profile.

Crucial for PMCHS: viral protein was also found in healthy controls — but their transcriptional response was minimal (38 dysregulated genes vs 122 in Long Covid patients). It is not the presence of the viral fragment that makes the difference — it is the terrain's response to that fragment.

Augustin et al., Mucosal Immunology, 2026 · DOI: 10.1016/j.mucimm.2026.03.002

Key study · Proal / Putrino / Mehandru

Terrain-dependent differential immune response

Using spatial transcriptomics on intestinal biopsies, this study confirms that the local immune environment around spike protein deposits is profoundly different in Long Covid patients vs controls. Dysregulated genes include markers linked to Crohn's disease and dysregulation of homeostatic chemokines — notably CXCL13, CCL19, CCL21 — whose scavenger receptor ACKR3 is precisely a risk gene identified in MCAS/hEDS GWAS.

This profile corresponds exactly to the PMCHS terrain: a mucosal immune system whose baseline regulation is already altered, and which cannot respond normally to viral persistence.

Proal, Putrino, Mehandru et al. · Preprint (méthodologie RNAscope + spatial transcriptomics)

⚠️ Important methodological note: Most Long Covid studies do not stratify their cohorts according to pre-existing mast cell terrain. This is precisely why results are heterogeneous and treatments poorly effective in the general population. PMCHS/non-PMCHS stratification would represent a major advance for Long Covid research.

Therapeutic convergence

The most promising approaches for Long Covid converge with the PMCHS stabilisation protocol — not by coincidence, but as confirmation of a shared mechanism.

Quercetin Mast cell stabiliser · inhibits spike/ACE2 binding · direct anti-inflammatory action. Already central to the PMCHS protocol.

Nattokinase Fibrinolytic enzyme · preliminary data on direct spike protein degradation. Most studied pathway for viral clearance in Long Covid.

Luteolin Stabilising flavonoid · reduces mast cell activation · neuroprotective properties documented in post-viral brain fog.

Intestinal barrier repair Larazotide (in trial) · zinc carnosine · glutamine · butyrate. Reducing permeability to limit viral fragment persistence in tissues.

H1+H2 antihistamines Cetirizine + famotidine combination shows documented efficacy in several Long Covid case series — exactly the PMCHS protocol combination.

Montelukast Leukotriene inhibitor · empirically used in Long Covid with positive results on fatigue and brain fog. Present in the PMCHS protocol.

Link to Encephalitis page

Long Covid and neuroinflammation

In the most severe Long Covid cases, chronic mast cell degranulation can cross the blood-brain barrier and activate microglial cells — leading to persistent neuroinflammation. This mechanism, documented in post-viral encephalitis, forms the mechanistic basis of severe brain fog, memory disorders, and neuropsychiatric symptoms of Long Covid.

→ See the ME/CFS & PMCHS page